うつ病ラットにおける海馬S100Bとシグナル経路ERKl/2NF‐κB発現に対するデュロキセチンの効果

Objective To analyze the effect of duloxetine on S100B and signal pathway ERK1/2-NF-κB expression in hippocampus in depression rat. Methods Chronic unpredictable mild stimulation was used to establish depressive model rats(n=50). They were randomly divided into no-intervention group(n=10), different treatment time of duloxetine group (C, D, E, F group, 10 rats in each group )and then 10 normal rats were selected as control group. Behavior tests including open-field test and the saccharine preference test were used to test the behavioral change of rats after 28 days intragastric administration. Western blot was used to detect S100B, t-ERK1/2, pERK1/2, t-NF-κB and pNF-κB expression in hippocampus. Results In open-field test, the crossing score, rearing score and latency of the rats in E, F group were (69.68±14.61) and (70.66±11.53) score, (20.94±10.92) and (20.32±8.85) score, (1.1±0.4)s and(1.0±0.4) s respectively, and showed no significant difference with those of control group ((71.19±12.08) score, (20.42±8.76) score, (1.0±0.3)s) after 28 d intragastric administration (P>0.05), while the level score, vertical score were significantly higher than those in depressive model (P<0.05). In the saccharine preference test, the rats in E, F and control group exhibited increased saccharin preference compared with depressive model rats (P<0.05). The rats in E, F and control group exhibited increased S100B, pERK1/2 and pNF-κB expression in hippocampus compared with depressive model rats (P<0.05). Conclusion Duloxetine improves the behavioral ability of depression rat and exerts effect after 2 weeks.The ERK1/2-NF-κB signal pathway in hippocampus may participate in this mechanism. Key words: Duloxetine; Depression; S100B; ERK1/2-NF-κB